Objective: Here we aimed to explore the progress of 18F-Florzolotau PET and its clinical relevance in patients with PSP during one-year follow-up.

Background: The 18F-Florzolotau PET presented impressive outperformance in the disease captures and clinical severity association of PSP in our previous cross-sectional studies. However, whether 18F-Florzolotau PET could be the predictive and real-time biomarker for the disease progression is still unclear.

Method: Based on our dynamic PSPNI cohort, patients were continuously enrolled from October 2018 to March 2022 and underwent longitudinal follow-up until October 2023. Further analysis was made in patients who had completed at least a 12-month interval of 18F-Florzolotau PET and MRI follow-up. Based on the new semi-quantification technique(PERSI), white matter was used as the reference region for calculating SUVR. The progression of different brain regions of interests was calculated by paired test. Partial correlation among the baseline or annual changes of 18F-Florzolotau PET SUVRs with clinical progression was analyzed after the correction of disease duration at baseline.

Results: There were finally 75 patients with PSP who completed T0 baseline and T1 follow-up, with matched clinical evaluation, included in this study. After one-year follow-up, the overall PSP cohort showed mild progress in globus pallidus and putamen compared to the baseline. As for the clinical correlation, there was significantly positive association between the baseline 18F-Florzolotau PET SUVRs in Raphe nuclei with the total score of the PSP rating scales (PSPrs) scale, and the scores in the subdomains of history, eye movement, gait and axial symptoms. Moreover, the annual change of 18F-Florzolotau PET SUVRs in globus pallidus and putamen were related to the annual change of Unified Parkinson’s Disease Rating Scale-III (UPDRS-III) scale.

Conclusion: Here we showed the one-year progress of 18F-Florzolotau PET in the overall PSP cohort and its potential disease predictive value, providing vital information for the clinical trial enrollment in the future. Nevertheless, further research still needs to be carried out, especially those extending the follow-up time, expanding the sample size, and considering disease heterogeneity in the future.

« Back to 2024 International Congress

MDS Abstracts - https://www.mdsabstracts.org/abstract/longitudinal-progress-and-clinical-relevance-of-18f-florzolutau-pet-in-patients-with-psp-a-one-year-follow-up-study/